Global targeted drug delivery device market is anticipated to reach to USD $2,153 Million by 2035 with CAGR of 19.7%

The prevalence of chronic diseases has increased significantly over the past few decades. Presently, around 129 million people in the US have at least one life threating chronic condition, such as heart disease, cancer, diabetes, obesity or hypertension.

The global targeted drug delivery device market size is projected to grow from $427 Million in 2026 to $2,153 Million by 2035, representing a CAGR of 19.7% during the forecast period.

Additionally, about 90% of the annual USD 4.1 trillion health care expenditure is attributed to managing and treating chronic diseases and mental health conditions. Thus, rising incidence of chronic diseases, coupled with aging population has led to a surge in the demand for novel drugs, including complex small molecules and biologics, across multiple therapeutic areas.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/targeted-drug-delivery/request-quote.html

The pharmaceutical industry is increasingly shifting towards biologics over traditional small molecule drugs due to their higher specificity and efficacy in treating complex diseases, particularly through targeted drug delivery devices. Biologics are designed to interact with specific cellular targets, which can lead to more effective treatments with fewer side effects. In 2023, the US FDA approved around 20 biologics for various indications, highlighting their growing acceptance. However, the administration of biologics often requires injections rather than oral routes, posing challenges for patient compliance. Further, over the years, biologics have demonstrated a high success rate (more than 70%) in various clinical trials across different therapeutic areas. As the industry continues to innovate, enhancing drug delivery systems will be crucial for maximizing the benefits of biologics.

To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/targeted-drug-delivery/request-sample.html

Advantages of targeted drug delivery device
Targeted Drug Delivery Devices offer a number of benefits. Some of the key advantages offered by these devices are summarized below:

 Minimally Invasive: Current systems for delivering cell therapies are often inefficient and require invasive procedures for direct injection into targeted tissues. For patients with conditions like heart failure, multiple invasive surgeries are required to achieve optimal therapeutic effects due to the need for several injections. In contrast, targeted drug delivery devices offer a solution by enabling localized therapies to be administered minimally invasively as many times as required. These devices are implanted into the target tissue through a single surgical procedure, after which the cells within the device's reservoir can produce therapeutic effects and facilitate the healing of damaged tissue. Additionally, catheter-based injection systems have been shown to effectively provide safe and minimally invasive targeted delivery of cell therapies.
Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/targeted-drug-delivery.html

 Limited Systemic Toxic Side-effects: Majority of the biologics, including cell therapies, gene therapies and immunotherapies are being delivered systemically rather than being delivered directly to the targeted site. The systemic administration of these therapies can cause toxicity by activating the immune response, resulting in adverse side effects such as fatigue, nausea, easy bruising, and infection. Additionally, patients often need to visit clinics every week or two for frequent repeated administrations of these therapies. The targeted drug delivery devices deliver the therapeutics to the targeted site easily, maximizing target site exposure, generate elicit efficient therapeutic response, and reduces the risk of immunogenicity.
 Sustained Delivery: The high tumoral pressure makes it challenging for a drug to be effective when administered directly to the tumor in a single dose. This is primarily due to the fact that only a small amount of drug gets reaches the targeted site while the remaining gets eliminated. The intra-tumoral implantable drug delivery devices represent a significant advancement in the field of cancer therapy by enabling sustained drug release. These systems are designed to release therapeutic agents at a controlled rate, significantly improving treatment efficacy and safety.
 Encapsulated Cell Therapy Implants: Targeted drug delivery via encapsulated cell therapy implants enables the safe and efficient administration of cell therapies. Encapsulation of therapeutic cells and their implantation into the surgical cavity allows for long term release of active compounds at the required site, reducing side effects associated with systemic delivery. Most encapsulation strategies also function as biomimetic scaffolds, providing the necessary structural support for cell survival and proliferation.

Research objectives:
• The Targeted Drug Delivery Device Market report studies the worldwide market consumption rate in terms of value and volume.
• It identifies the various sub-segments of the market structure.
• It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline.
• The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges.
• Furthermore, the report underpins the strategic developments occurring in the global market, such as expansions, mergers & acquisitions, agreements, as well as new product launches.

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.